Biomarkers in medical imaging are the key to detecting and treating cancer

Press release

MEDIAN Technologies coauthors a poster to be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (June 3-7 in Chicago, IL)

*The poster on computer-aided volumetry analysis will be presented by the University of Minnesota during the June 6 "Tumor Biology" session.*

**Sophia Antipolis, Nice (France), May 31, 2010** – MEDIAN Technologies (ALMDT), the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced that it is a coauthor on a poster to be presented at the 2011 Annual Congress of the American Society of Clinical Oncology (ASCO), to be held June 3-7 at the McCormick Place venue in Chicago, IL.

Together with researchers at the University of Minnesota, MEDIAN Technologies has written a poster entitled "Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria". The poster (#10593) will be presented between 8 am and noon on June 6, during the "Tumor Biology" session in Hall A.

For more information on the poster, visit: [http://abstract.asco.org/AbstView_102_83027.html](http://abstract.asco.org/AbstView_102_83027.html)

"The ASCO annual meeting is an event that experts in this field cannot afford to miss and we are particularly pleased that the University of Minnesota researchers will be presenting this poster", commented MEDIAN Technologies’ Chairman and CEO Fredrik Brag. "This is an especially strategic presentation because the research is a perfect illustration of our CTIS solution for performing clinical trials in oncology, which will be presented at the ASCO meeting for the first time this year", he added.

The authors are: L. Ding, R. L. Bliss, M. Ingebrand, T. Allen, P. Ives, A. Dudek, R. A. Kratzke; University of Minnesota, Minneapolis, MN; MEDIAN Technologies Inc., Minneapolis, MN; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.

**About MEDIAN Technologies**

MEDIAN Technologies was founded in 2002 by Fredrik Brag (the current Chairman and CEO), Gérard Milhiet and Arnaud Butzbach. It is based at Sophia Antipolis (in the south of France) and has a subsidiary in the USA. The company currently has a staff of 40, over half of whom work in R&D.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients. It is targeting both the oncology clinical trials market (its prime market) and the patient care market.
Biomarkers in medical imaging are the key to detecting and treating cancer

MEDIAN Technologies collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN Technologies has been present in the market since 2007 through direct sales of its lesion management solutions and alliances with specialist cancer centers in Europe and the USA.

Since its incorporation, the company has raised about €26 million including 10 million during its successful IPO on NYSE Alternext in May 2011 and 16 million in three rounds of financing (in 2003, 2004 and 2006/7) with major internationally respected investors, including Draper Fisher Jurvetson ePlanet Ventures (DFJ) (USA), Idinvest Partners / AGF Private Equity (France), Auriga Partners (France) and the University of Chicago Hospitals (USA). MEDIAN Technologies also benefited from €2.8 million in financial support awarded to its LESIO project by OSEO (the French state innovation agency) over the period 2008-2010 and has been accredited as an "innovative company" by the agency.

For more information about MEDIAN, visit www.mediantechnologies.com.

Contacts Presse

MEDIAN Technologies
Fredrik Brag, CEO
+33 492 906 582
fredrik.brag@mediantechnologies.com

ALIZE RP
Caroline Carmagnol
+ 33 664 189 959 / + 33 142 688 643
caroline@alizerp.com

Anne-Sophie Cosquéric and Georges-Antoine Gary
+ 33 1 42 68 86 41 or 40
anne-sophie@alizerp.com
georges-antoine@alizerp.com